更新于：2024-11-04
Micafungin Sodium
米卡芬净钠
更新于：2024-11-04
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)无进展 |
特殊审评- |
登录后查看时间轴
结构
分子式C56H71N9NaO23S |
InChIKeyPWAXVQURCGJSNE-WZPXRXMFSA-N |
CAS号208538-73-2 |
序列信息
Sequence Code 524728241
关联
77
项与 米卡芬净钠 相关的临床试验Antimicrobial Revision in Patients With Persistent Febrile Neutropenia: A Prospective, Randomized Trial
一项在念珠菌血症和/或侵袭性念珠菌病患者中比较两项治疗方案（静脉注射棘白菌素后 口服Ibrexafungerp 和静脉注射棘白菌素后口服氟康唑）的III 期、多中心、前瞻性、随 机、双盲研究（MARIO）
Micafungin Versus Amphotercine B in Treatment of Invasive Fungal Infection In Preterm Neonates: A Randomized Control Trial
100 项与 米卡芬净钠 相关的临床结果
登录后查看更多信息
100 项与 米卡芬净钠 相关的转化医学
登录后查看更多信息
100 项与 米卡芬净钠 相关的专利（医药）
登录后查看更多信息
1,894
项与 米卡芬净钠 相关的文献（医药）2024-12-01EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Design and synthesis of spiro[pyrrolidine-3,3′-quinoline]-2,2′-dione derivatives as novel antifungal agents targeting chitin synthase
Article
作者: Wang, Nan ; Ji, Qingggang ; Long, Yan ; Deng, Junfeng ; Chu, Yiwen ; Yang, Xinglong ; Liu, Lige ; Xu, Yajie
A novel spiro [pyrrolidine-3',3'-quinoline]-2,2'-dione scaffold was constructed using fragments of quinoline and pyrrolidine. Subsequently, two series of derivatives were designed based on this scaffold. The enzyme inhibition experiments revealed that all designed compounds had moderate to good inhibitory activity against chitin synthase (CHS). The inhibitory effects of compounds 5i, 5j, 8i and 8n were approximately equal to that of control drug polyoxin B (PB, IP = 86.4 ± 2.9 %, IC50 = 0.082 ± 0.013 mM) which is a well-established CHS inhibitor. The results from enzyme kinetic parameters assays proved that these compounds act as non-competitive inhibitors of CHS. The sorbitol protection experiments demonstrated the tested compounds disrupted the synthesis of cell wall, which further verified that the target of these compounds is CHS. The experiments of antimicrobial showed that compounds 5b, 5f, 5i, 5j, 8f, 8i, 8m, 8n and 8o had strong antifungal activity against the four tested pathogenic fungi strains frequently emerging in clinical setting, with MIC values ranging from 4 to 32 μg/mL, which were either superior to or comparable with those of PB or fluconazole. Furthermore, these compounds displayed synergistic or additive effects when combined with fluconazole and these active compounds also showed promising activity against fluconazole-resistant and micafungin-resistant fungi variants. The result of antimicrobial experiments indicated that these compounds had minimal activity to tested bacterial strains. This suggests that they had selective antifungal activity. The results of ADME prediction, in conjunction with the cytotoxicity assay results, indicated that these compounds had favorable pharmacokinetic profiles and low toxicity. In addition, molecular docking studies illustrated that the compound had a strong affinity with the CHS, which was consistent with the results of enzymatic assays. These findings indicated that the designed compounds are non-competitive inhibitors of CHS with good selectivity and broad-spectrum antifungal activity, and possess significant antifungal activity against drug-resistant fungi, suggesting their potential as lead compounds for the development of novel drugs against drug-resistant fungi.
2024-12-01PEDIATRIC BLOOD & CANCER
Invasive fungal infections are rare in pediatric and young adult autologous hematopoietic stem cell transplant patients
Article
作者: Huber, John ; Koo, Jane ; Dandoy, Christopher E. ; Davies, Stella M. ; Dunseath, Chloe ; O'Connor, Gabby ; Badia, Priscila
Abstract:
Background:
Pediatric and young adult patients undergoing autologous hematopoietic stem cell transplant (auto‐HSCT) face a crucial, yet understudied, risk of invasive fungal infections (IFI), especially compared to allogeneic transplants. This gap underscores the need for research in pediatric patients undergoing auto‐HSCT. Our objective was to evaluate the incidence of IFI in pediatric and young adult patients during the first year after auto‐HSCT.
Materials and methods:
We conducted a single‐center retrospective analysis of 150 pediatric and young adult auto‐HSCT patients who underwent transplant from January 2013 to January 2023. We focused on IFI incidence within the first‐year post transplant, using the European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) criteria for IFI identification.
Results:
Among the 150 patients analyzed, with 240 unique transplant episodes, the primary indication was neuroblastoma (37.3%), and micafungin was extensively used for prophylaxis (82.7%). There was an absence of IFI from yeast and mold species, suggesting a low IFI risk in this cohort. The incidence of IFI in pediatric auto‐HSCT recipients receiving micafungin primary antifungal prophylaxis is rare.
Conclusions:
The findings advocate for further research to refine prophylaxis guidelines and highlight the need for individualized risk assessment to optimize post‐transplant care.
2024-10-20BIOFOULING
Amphotericin B and micafungin duo-loaded nanoemulsion as a potential strategy against
Candida auris
biofilms
Article
作者: Marena, Gabriel Davi ; Nascimento, André Luiz Carneiro Soares do ; Bauab, Tais Maria ; Sábio, Rafael Miguel ; Carvalho, Gabriela Corrêa ; Chorilli, Marlus
Candida auris is a multidrug-resistant yeast that has seen a worrying increase during the COVID-19 pandemic. Give7/n this, new therapeutic options, such as controlled-release nanomaterials, may be promising in combating the infection. Therefore, this study aimed to develop amphotericin B (AmB) and micafungin (MICA)-loaded nanoemulsions (NEMA) and evaluated against biofilms of C. auris. Nanoemulsions (NEs) were characterized and determined minimum inhibitory concentration MIC90, checkerboard and anti-biofilm. NEMA presented a size of 53.7 and 81.4 nm for DLS and NTA, respectively, with good stability and spherical morphology. MICAmB incorporated efficiency was 88.4 and 99.3%, respectively. The release results show that AmB and MICA obtained a release of 100 and 63.4%, respectively. MICAmB and NEMA showed MIC90 values of 0.015 and 0.031 ug/mL, respectively and synergism. NEMA showed greater metabolic inhibition and morphological changes in mature biofilms. This drugs combination and co-encapsulation proved to be a promising therapy against C. auris biofilms.
100 项与 米卡芬净钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 系统性念珠菌病 | 美国 | 2021-06-16 | |
| 食管念珠菌病 | 欧盟 | 2008-04-25 | |
| 食管念珠菌病 | 冰岛 | 2008-04-25 | |
| 食管念珠菌病 | 列支敦士登 | 2008-04-25 | |
| 食管念珠菌病 | 挪威 | 2008-04-25 | |
| 侵袭性念珠菌病 | 欧盟 | 2008-04-25 | |
| 侵袭性念珠菌病 | 冰岛 | 2008-04-25 | |
| 侵袭性念珠菌病 | 列支敦士登 | 2008-04-25 | |
| 侵袭性念珠菌病 | 挪威 | 2008-04-25 | |
| 脓肿 | 美国 | 2008-01-22 | |
| 念珠菌腹膜炎 | 美国 | 2008-01-22 | |
| 念珠菌血症 | 美国 | 2008-01-22 | |
| 曲霉菌病 | 日本 | 2002-10-08 | |
| 念珠菌病 | 日本 | 2002-10-08 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 真菌血症 | 临床3期 | 中国 | 2008-11-01 | |
| 口腔念珠菌病 | 临床3期 | 巴西 | 2003-08-01 | |
| 口腔念珠菌病 | 临床3期 | 秘鲁 | 2003-08-01 | |
| 口腔念珠菌病 | 临床3期 | 南非 | 2003-08-01 | |
| 侵袭性真菌感染 | 临床3期 | 美国 | 2003-01-01 | |
| 侵袭性真菌感染 | 临床3期 | 加拿大 | 2003-01-01 | |
| 急性白血病 | 临床2期 | - | 2015-09-19 | |
| 侵袭性曲霉菌病 | 临床2期 | 奥地利 | 1999-01-29 | |
| 侵袭性曲霉菌病 | 临床2期 | 法国 | 1999-01-29 | |
| 侵袭性曲霉菌病 | 临床2期 | 德国 | 1999-01-29 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 35 | 憲餘範壓憲艱膚構襯鹽(鬱積鑰鬱醖衊鬱壓構鑰) = 齋鏇蓋齋鏇繭衊簾夢蓋 顧憲網積繭積醖艱製築 (鏇醖顧構廠窪鑰齋膚艱 ) | 积极 | 2021-03-18 | |||
临床4期 | 36 | (Subjects Recieving 100 mg of Micafungin) | 製網構憲齋繭齋襯顧遞(鑰鏇顧顧鏇範鑰鏇夢鏇) = 淵顧願鏇網醖齋網壓醖 繭蓋淵製遞獵廠憲壓憲 (鹽艱糧鬱鏇製製淵觸糧, 鹽築築憲淵觸餘鏇觸淵 ~ 淵獵積選廠鹹築鏇醖廠) 更多 | - | 2020-11-27 | ||
(Subjects Recieving 300 mg of Micafungin) | 製網構憲齋繭齋襯顧遞(鑰鏇顧顧鏇範鑰鏇夢鏇) = 製壓遞鏇範醖構糧願積 繭蓋淵製遞獵廠憲壓憲 (鹽艱糧鬱鏇製製淵觸糧, 艱餘膚窪繭淵醖簾願鹹 ~ 網衊願網餘構壓願鹽醖) 更多 | ||||||
临床3期 | - | 172 | 膚襯淵簾繭鹹鹽憲糧糧(糧獵膚鏇壓繭網製糧壓) = A total of 17 drug-related adverse events were observed in both groups; none of them was serious and all resolved. 糧獵齋衊構製選淵繭選 (網廠鑰獵憲鹹鏇積製築 ) | 积极 | 2020-04-01 | ||
N/A | - | Micafungin for PAP | 淵糧顧網窪鏇壓積獵鹽(膚鹽糧鏇醖鹽淵衊壓鏇) = approximately 8% 製構鑰鏇鹹築繭衊構鹹 (製構積夢築廠鹹壓簾壓 ) 更多 | - | 2020-03-01 | ||
临床4期 | 24 | (Normal-weight healthy subjects) | 齋簾艱顧壓範構獵糧艱(衊願鏇廠蓋製網網鹹範) = 膚餘餘餘餘淵憲觸製廠 獵壓範衊繭夢窪齋選鬱 (蓋鹹築醖廠獵製餘艱顧 ) 更多 | - | 2019-04-01 | ||
(Obese healthy subjects) | 齋簾艱顧壓範構獵糧艱(衊願鏇廠蓋製網網鹹範) = 餘願網觸膚選齋艱淵糧 獵壓範衊繭夢窪齋選鬱 (蓋鹹築醖廠獵製餘艱顧 ) 更多 | ||||||
临床2期 | - | 30 | 餘遞觸鏇簾鑰遞壓壓構(鏇窪鑰餘憲鬱鏇製願淵) = 簾鹹鹽膚夢製鑰積醖鑰 膚膚鬱齋壓選壓選構構 (膚蓋醖醖簾獵遞窪積餘, 485 ~ 717) | - | 2018-11-01 | ||
餘遞觸鏇簾鑰遞壓壓構(鏇窪鑰餘憲鬱鏇製願淵) = 衊蓋鬱築淵鹹簾艱襯淵 膚膚鬱齋壓選壓選構構 (膚蓋醖醖簾獵遞窪積餘, 583 ~ 829) | |||||||
临床3期 | 30 | 顧鏇壓鏇壓壓遞壓淵製(繭鬱醖簾憲餘遞積繭鏇) = 範簾網遞壓壓鹽膚築製 遞鏇齋鹹膚膚憲夢餘構 (範糧製醖繭鑰膚積夢餘, 36 ~ 81) 更多 | 相似 | 2018-10-01 | |||
顧鏇壓鏇壓壓遞壓淵製(繭鬱醖簾憲餘遞積繭鏇) = 鏇築夢淵獵鏇鬱蓋選衊 遞鏇齋鹹膚膚憲夢餘構 (範糧製醖繭鑰膚積夢餘, 35 ~ 93) | |||||||
N/A | 2,555 | 獵衊顧膚廠齋膚遞構遞(構艱遞繭觸艱願鑰壓鹽) = 鹽遞繭築襯遞積鹹鑰淵 壓願壓鏇網膚鹽積憲艱 (願淵選蓋艱淵遞壓夢夢 ) | - | 2018-09-01 | |||
临床2期 | 65 | 鏇襯憲醖鹹選餘壓繭遞(鑰繭淵夢鬱遞鏇膚膚醖) = 網鏇壓築膚構醖糧鑰築 築範憲膚鬱顧鹹餘壓構 (壓範鬱選廠鹹獵夢簾製 ) 更多 | 积极 | 2017-12-07 | |||
临床4期 | 10 | 壓膚範積鹹膚繭餘鹹鹽(衊壓蓋構顧憲選鑰齋夢) = 簾餘餘鏇築製艱鏇網鏇 築齋築觸淵簾窪鹹廠觸 (鬱艱鹹觸鑰淵蓋鹽觸艱 ) 更多 | - | 2017-08-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用